Key Takeaways
- • TR Capital portfolio company Pharmacity secures growth capital from LeapFrog Investments in an undisclosed funding round, with market sources indicating the deal size approximates $50–80 million in a mix of equity and debt financing to accelerate nationwide expansion.
- • Pharmacity achieved EBITDA profitability in Q4 2025 and sustained momentum into Q1 2026, recording over 35% year-on-year revenue growth and more than 20% same-store sales growth, marking successful operational turnaround under TR Capital stewardship.
- • Vietnam's largest pharmacy chain operates 1,100+ stores across major urban centers and Tier II/Tier III cities, serving nearly 19 million loyal customers with a portfolio of 7,000+ active products, positioned as a leading consolidator in the country's retail pharmacy sector.
- • Deepanshu Madan, Partner at TR Capital, serves as CEO and led the company turnaround following TR Capital's acquisition, demonstrating active portfolio management by the secondary PE investor to drive value creation.
- • LeapFrog Investments' commitment reflects sustained institutional capital appetite for healthcare-focused businesses in emerging markets, with the deal signaling confidence in Vietnam's consumer healthcare sector growth trajectory.
Summary
TR Capital announced on May 28, 2026, that Pharmacity, a portfolio company within its secondary private equity platform, has raised growth capital from LeapFrog Investments, a healthcare and financial services-focused PE firm operating in emerging markets. The transaction underscores continued institutional investor interest in Vietnam's consumer pharmacy retail sector and marks a significant milestone in Pharmacity's development trajectory. Market sources indicate the funding round totals approximately $50–80 million in a combination of equity and debt, though the companies have not disclosed the final deal size.
Pharmacity, founded in 2011, has scaled into Vietnam's largest modern pharmacy retail chain, operating more than 1,100 stores across major metropolitan areas and lower-tier cities nationwide. The business serves approximately 19 million loyal customers and maintains a portfolio of over 7,000 active products supported by technology-enabled operations and disciplined supply chain infrastructure. Under the leadership of Deepanshu Madan, who assumed the CEO role at TR Capital's behest to spearhead the operational turnaround, the company has delivered sustained performance improvements. Pharmacity achieved EBITDA profitability in the fourth quarter of 2025 and extended positive momentum into the first quarter of 2026, with revenue growth exceeding 35% year-over-year and same-store sales growth surpassing 20%. Recent store cohorts are progressing toward EBITDA breakeven, reflecting improved unit economics and disciplined site selection.
The capital raise follows a multi-year value creation engagement by TR Capital, the Asia-Pacific region's leading secondary PE investor. LeapFrog Investments' commitment to the growth round reflects institutional confidence in Pharmacity's operational model and expansion potential within Vietnam's consumer healthcare market. The transaction demonstrates the secondary PE investment model's effectiveness in driving portfolio company transformation and positioning assets for subsequent growth capital rounds. For TR Capital investors, the deal validates the firm's ability to identify undervalued or distressed assets and execute successful operational turnarounds that attract follow-on institutional capital.
Pharmacity, founded in 2011, has scaled into Vietnam's largest modern pharmacy retail chain, operating more than 1,100 stores across major metropolitan areas and lower-tier cities nationwide. The business serves approximately 19 million loyal customers and maintains a portfolio of over 7,000 active products supported by technology-enabled operations and disciplined supply chain infrastructure. Under the leadership of Deepanshu Madan, who assumed the CEO role at TR Capital's behest to spearhead the operational turnaround, the company has delivered sustained performance improvements. Pharmacity achieved EBITDA profitability in the fourth quarter of 2025 and extended positive momentum into the first quarter of 2026, with revenue growth exceeding 35% year-over-year and same-store sales growth surpassing 20%. Recent store cohorts are progressing toward EBITDA breakeven, reflecting improved unit economics and disciplined site selection.
The capital raise follows a multi-year value creation engagement by TR Capital, the Asia-Pacific region's leading secondary PE investor. LeapFrog Investments' commitment to the growth round reflects institutional confidence in Pharmacity's operational model and expansion potential within Vietnam's consumer healthcare market. The transaction demonstrates the secondary PE investment model's effectiveness in driving portfolio company transformation and positioning assets for subsequent growth capital rounds. For TR Capital investors, the deal validates the firm's ability to identify undervalued or distressed assets and execute successful operational turnarounds that attract follow-on institutional capital.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.